Skip to main content
Alphamab Oncology logo

Alphamab Oncology — Investor Relations & Filings

Ticker · 9966 ISIN · KYG0330A1013 LEI · 254900VOW925DTFGNA02 HKEX Manufacturing
Open in API
Filings indexed 361 across all filing types
Latest filing 2026-04-28 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 9966

About Alphamab Oncology

http://www.alphamabonc.com

Alphamab Oncology is an innovative biopharmaceutical company specializing in the research, development, and commercialization of differentiated anti-tumor biotherapeutics. The company is dedicated to addressing unmet clinical needs in oncology by developing effective, safe, and globally competitive cancer therapies. A core unique selling point is its proprietary technology platform for Antibody-Drug Conjugates (ADCs). This platform utilizes site-specific conjugation via Fc glycan, employing a one-enzyme, two-step process to produce ADCs with a highly uniform Drug-to-Antibody Ratio (DAR). This method results in superior serum stability and enhanced bystander killing effect, aiming to widen the therapeutic window and minimize toxic side effects. Key pipeline assets include KN035 and the biparatopic HER2-targeting ADC, JSKN003, which has received Breakthrough Therapy Designation from the FDA.

Recent filings

Filing Released Lang Actions
2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
Regulatory Filings
2026-04-28 English
2025 Annual Report
Regulatory Filings
2026-04-28 English
GRANT OF AWARD SHARES UNDER THE RESTRICTED SHARE AWARD SCHEME
Share Issue/Capital Change Classification · 1% confidence The document is a Hong Kong Stock Exchange announcement concerning the grant of restricted award shares under the company’s employee share award scheme. It details the number of shares to be issued, vesting schedules, and other terms—i.e., a new share issuance under the company’s capital structure. This falls under ‘Share Issue/Capital Change’ rather than a financial report or AGM material.
2026-04-23 English
WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES
Board/Management Information Classification · 1% confidence The document is a corporate announcement from Alphamab Oncology regarding a waiver from strict compliance with listing rules and the appointment of a new joint company secretary. It concerns senior management change and waiver conditions under the listing rules. This is not a full report but a management/board‐level announcement, fitting the Board/Management Information category.
2026-04-22 English
VOLUNTARY ANNOUNCEMENT - SELECTION OF RESULTS OF PHASE III CLINICAL STUDY OF KN026 FOR NEOADJUVANT TREATMENT OF BC FOR LBA ORAL SESSION PRESENTATION AT 2026 ASCO ANNUAL MEETING
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement by Alphamab Oncology regarding the selection of clinical trial results for presentation at an upcoming oncology conference. It contains no financial results, governance changes, voting outcomes, capital transactions, or other specific filing content. It is neither an earnings release nor an investor presentation, but a general business update. No other category applies more closely. Therefore it falls into the fallback category of a general regulatory announcement (RNS).
2026-04-22 English
(1) CHANGE OF JOINT COMPANY SECRETARY AND AUTHORIZED REPRESENTATIVE; AND (2) WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES
Board/Management Information Classification · 1% confidence The document is an official announcement by Alphamab Oncology concerning the resignation and appointment of its joint company secretary and authorized representative under the Listing Rules, including biographical details of the incoming officer and waiver application. It does not present financial results or full reports, nor solicit votes. It clearly falls under changes in senior management/board-related corporate governance roles. Therefore, it is classified as a Board/Management Information release (MANG).
2026-04-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.